The clinical translation of blood biomarkers for Alzheimer's disease: Timing and challenges.
作者信息
Huang Shan, Wang Jun, Guo Tengfei, Wang Yan-Jiang
机构信息
Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Army Medical University, Chongqing, China.
Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China.
出版信息
Alzheimers Dement. 2025 Aug;21(8):e70478. doi: 10.1002/alz.70478.
Abstract
摘要
相似文献
1
The clinical translation of blood biomarkers for Alzheimer's disease: Timing and challenges.阿尔茨海默病血液生物标志物的临床转化：时机与挑战。
Alzheimers Dement. 2025 Aug;21(8):e70478. doi: 10.1002/alz.70478.
2
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用：系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
3
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍（MCI）患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
4
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍（MCI）患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
5
Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference.基因决定的阿尔茨海默病研究进展：2024年唐氏综合征与常染色体显性阿尔茨海默病会议
Alzheimers Dement. 2025 Jul;21(7):e70309. doi: 10.1002/alz.70309.
6
MicroRNA and Alzheimer's disease: Diagnostic biomarkers and potential therapeutic targets.微小RNA与阿尔茨海默病：诊断生物标志物及潜在治疗靶点
Neural Regen Res. 2025 Jul 5. doi: 10.4103/NRR.NRR-D-25-00002.
7
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
8
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
9
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
10
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.唐氏综合征与常染色体显性阿尔茨海默病患者 Tau 蛋白扩散的比较：一项横断面研究。
Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X.
本文引用的文献
1
Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes.路易体痴呆亚型的神经影像学和血浆生物标志物差异与共性
Alzheimers Dement. 2025 May;21(5):e70274. doi: 10.1002/alz.70274.
2
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers.阿尔茨海默病血液生物标志物的认知表型分析与解读
JAMA Neurol. 2025 May 1;82(5):506-515. doi: 10.1001/jamaneurol.2025.0142.
3
Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.血浆p-tau217/Aβ42对临床和社区队列中阿尔茨海默病的诊断准确性
Alzheimers Dement. 2025 Mar;21(3):e70038. doi: 10.1002/alz.70038.
4
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.阿尔茨海默病协会全球生物标志物标准化联盟（GBSC）血浆磷酸化tau蛋白循环检验研究。
Alzheimers Dement. 2025 Feb;21(2):e14508. doi: 10.1002/alz.14508. Epub 2025 Feb 5.
5
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.关键血浆磷酸化tau 217生物标志物检测的全面直接比较。
Brain. 2025 Feb 3;148(2):416-431. doi: 10.1093/brain/awae346.
6
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
7
Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.阿尔茨海默病血液生物标志物：研究设计、样本采集、处理、生物样本库、测量和结果报告的实用指南。
Mol Neurodegener. 2024 May 15;19(1):40. doi: 10.1186/s13024-024-00711-1.
8
2024 Alzheimer's disease facts and figures.2024 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.
9
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
10
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.阿尔茨海默病相关血液生物标志物检测前样本处理影响的特征分析：来自阿尔茨海默病血液生物标志物标准化（SABB）工作组的结果。
Alzheimers Dement. 2022 Aug;18(8):1484-1497. doi: 10.1002/alz.12510. Epub 2021 Nov 29.
Zotero 插件